Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 209,895,810 papers from all fields of science
Search
Sign In
Create Free Account
RoActemra®
Known as:
RoActemra
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
A Case of Adult-Onset Still’s Disease Caused by a Novel Splicing Mutation in TNFAIP3 Successfully Treated With Tocilizumab
Dylan Lawless
,
Shelly Pathak
,
T. Scambler
,
L. Ouboussad
,
R. Anwar
,
S. Savic
Frontiers in Immunology
2018
Corpus ID: 49562849
TNFAIP3 encodes the NF-κB regulatory protein A20. High-penetrance heterozygous mutations in TNFAIP3 cause a haploinsufficiency of…
Expand
2018
2018
Differential role of Interleukin-1 and Interleukin-6 in K-Ras-driven pancreatic carcinoma undergoing mesenchymal transition
I. Siddiqui
,
M. Erreni
,
+8 authors
P. Allavena
Oncoimmunology
2018
Corpus ID: 26003083
ABSTRACT K-Ras mutations are a hallmark of human pancreatic adenocarcinoma (PDAC) and epithelial-mesenchymal-transition (EMT) is…
Expand
Review
2017
Review
2017
Tocilizumab: A Review in Rheumatoid Arthritis
L. Scott
Drugs
2017
Corpus ID: 20062868
Intravenous (IV) and subcutaneous (SC) tocilizumab (RoActemra®), an IL-6 receptor antagonist, are approved (± methotrexate) in…
Expand
Review
2016
Review
2016
The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
J. Shepherd
,
K. Cooper
,
P. Harris
,
J. Picot
,
Micah Rose
Health Technology Assessment
2016
Corpus ID: 3874337
BACKGROUND Juvenile idiopathic arthritis (JIA) is characterised by joint pain, swelling and a limitation of movement caused by…
Expand
Review
2013
Review
2013
A review of cost–effectiveness evaluations as part of national health technology assessments of biologic DMARDs in the treatment of rheumatoid arthritis
S. Iannazzo
,
M. De Francesco
,
D. Gomez-Ulloa
,
M. Benucci
Expert review of pharmacoeconomics & outcomes…
2013
Corpus ID: 207190912
Rheumatoid arthritis (RA) is an autoimmune chronic disease which is associated with an increasing disability in patients and high…
Expand
Review
2013
Review
2013
Intravenous Tocilizumab: A Review of Its Use in Adults with Rheumatoid Arthritis
Sohita Dhillon
BioDrugs
2013
Corpus ID: 5944786
Tocilizumab (Actemra®, RoActemra®) is a humanized monoclonal antibody that acts as an interleukin-6 receptor antagonist…
Expand
Highly Cited
2012
Highly Cited
2012
Is Tocilizumab an Effective Option for Treatment of Refractory Uveitis Associated with Juvenile Idiopathic Arthritis?
C. Tappeiner
,
C. Heinz
,
G. Ganser
,
A. Heiligenhaus
Journal of Rheumatology
2012
Corpus ID: 36001369
To the Editor: Anti-interleukin 6 receptor (anti-IL-6R) antibodies have been effective in experimental models of autoimmune…
Expand
Review
2011
Review
2011
Tocilizumab: A Novel Humanized Anti-Interleukin 6 Receptor Antibody for the Treatment of Patients with Rheumatoid Arthritis
R. Alten
Therapeutic Advances in Musculoskeletal Disease
2011
Corpus ID: 8591212
Tocilizumab (TCZ; RoActemra® or Actemra®) is a recombinant humanized monoclonal antibody that acts as an interleukin 6 (IL-6…
Expand
Review
2009
Review
2009
Tocilizumab: a review of its use in the management of rheumatoid arthritis.
Vicki Oldfield
,
Sohita Dhillon
,
G. Plosker
Drugs
2009
Corpus ID: 195689906
Tocilizumab (RoActemra or Actemra) is a recombinant humanized monoclonal antibody that acts as an interleukin (IL)-6 receptor…
Expand
Review
2009
Review
2009
▼Tocilizumab for rheumatoid arthritis
Amy Ka Man Yung
,
D. Ng
Drug and therapeutics bulletin
2009
Corpus ID: 29772167
▼Tocilizumab (RoActemra – Roche) is a new biological agent available in the UK for the treatment of adults with rheumatoid…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE